1.Research and implementation of integrated course of medical introduction I centered on organ systems
Siqing FU ; Hanjiao YAN ; Xiaoli WANG
Chinese Journal of Medical Education Research 2013;(1):27-30
The integrated course centered on organ system has been implemented for several years in Huazhong university of science and technology.Basic medicine courses were divided into three modules.Medical introduction Ⅰ was the first one which integrated nine basic medicine courses.Reform on teaching methods,teaching content,teacher training and experiment teaching were conducted and initial results were achieved.
2.Practice and reflection of pathophysiology teaching based on curriculum integration of organ system
Xinwen ZHOU ; Fuyuan CAO ; Qun WANG ; Ying YANG ; Hanjiao YAN
Chinese Journal of Medical Education Research 2021;20(3):266-270
In order to prevent the teaching reform of organ system curriculum from fall of teaching quality, the teaching effect of organ system curriculum and subject curriculum system in teaching the basic knowledge of pathophysiology was compared. In organ system curriculum teaching, there was no difference between the grades of students in Batch 2011 and Batch 2012 who conformed to the teaching principle of "gradual improvement" and those of the students taught with subject curriculum system. On the contrary, the students of Batch 2013 and Batch 2014 with insufficient curriculum content integration had a decreasing trend or a significant reduction in the teaching effect of organ system curriculum compared with that of subject curriculum system. After the supplementary for curriculum knowledge was made, the teaching effect of the organ system was significantly improved, which was better than that of the subject curriculum system. In conclusion, we have summarized and reflected on the effectiveness of the teaching reform of organ system curriculum, once again proved that basic medical teaching must also follow the inherent law of medical education, which is the teaching principle of "gradual improvement."
3.Three-Dimensional Conformal Radiation Therapy Combined with Tegafur for 32 Cases of Locally Recurrent Rectal Cancer
Chengrong SHU ; Ailing CAO ; Yong ZHANG ; Hanjiao WANG ; Jian ZHOU ; Ling HE
Herald of Medicine 2015;(4):452-454
Objective To evaluate the safety and feasibility of three-dimensional conformal radiation therapy combined with tegafur in treating locally recurrent rectal cancer. Methods A total of 32 patients with locally recurrent rectal cancer were treated with chemoradiotherapy ( CRT) . Radiotherapy was delivered to a total of 45 Gy in 25 fractions followed by a boost of 18 Gy in 10 fractions using three dimensional radiotherapy planning. Tegafur was given orally[80 mg·(m2)-1·d-1] on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47 during radiotherapy. Results Most of the adverse effects were mild. Grade 3-4 toxic effects occurred in 12. 5% of patients. Thirty-one patients completed full course of CRT, while one patient discontinued chemotherapy due to Grade 4 thrombocytopenia. There were 3 cases (9. 4%) with complete response, 21 cases (65. 6%) with partial response, and the overall response rate was 75. 0%. Overall pain response (complete and partial pain relief) was achieved in 96. 9% of patients. The 1- and 2-year overall survival rate was 71. 0% and 56. 5%, respectively. Conclusion 3D-CRT combined with tegafur for locally recurrent rectal cancer is feasible with high patient compliance and tolerable toxicities.
4.Construction of a nomogram prediction model for survival prognosis of patients with advanced non-small cell lung cancer after PD-1 inhibitor treatment
Xiongbing LI ; Ruifen ZHOU ; Jiali LI ; Hanjiao WANG ; Chao WANG ; Jing LI ; Zhe CAO ; Chengrong SHU
International Journal of Laboratory Medicine 2023;44(24):2975-2979
Objective To explore the effect of neutrophil to lymphocyte ratio(NLR)and other related in-dicators on the prognosis of advanced non-small cell lung cancer patients treated with programmed death 1(PD-1)inhibitor and construct a nomogram prediction model.Methods A total of 198 patients with advanced non-small cell lung cancer who received PD-1 inhibitor treatment in the hospital from February 2020 to April 2022 were selected and followed up to August 2022.According to the clinical outcome,they were divided into the death group(46 cases)and the survival group(152 cases).The clinical data of the death group and the survival group were recorded,and the prognostic factors of advanced non-small cell lung cancer patients trea-ted with PD-1 inhibitor were analyzed.Receiver operating characteristic(ROC)curve was used to analyze the predictive value of NLR,platelet to lymphocyte ratio(PLR)and lymphocyte to monocyte ratio(LMR)for the prognosis of patients.Multivariate Logistic regression model was used to analyze the independent risk factors affecting the prognosis of patients.A prediction nomogram model for the prognosis of patients was construc-ted using R software 4.0"rms"package,and the calibration curve was used to internally validate the nomo-gram prediction model.Results Compared with the survival group,the proportion of smoking,TNM stageⅣ,ECOG score 2,and NLR,PLR,LMR were higher(P<0.05).The area under the curve of NLR,PLR and LMR were 0.707,0.793 and 0.819,respectively,and the optimal cut-off value were 4.72%,179.21%and 3.44%,respectively.Smoking,TNM stage,ECOG score,NLR,PLR,and LMR were independent risk factors for the prognosis of advanced non-small cell lung cancer patients treated with PD-1 inhibitor(P<0.05).The internal validation results show that the nomogram inhibitor treatment of PD-1 model prediction the prognosis of patients with advanced non-small cell lung cancer C-index was 0.847(95%CI 0.769-0.902),the calibra-tion curve tends to be the ideal curve.The threshold value of the nomogram model for predicting the prognosis of patients with advanced non-small cell lung cancer treated with PD-1 inhibitor was>0.22.The nomogram prediction model provided a net clinical benefit,and the net clinical benefit was higher than that of smoking,TNM stage,ECOG score,NLR,PLR and LMR.Conclusion Based on smoking,TNM stage,ECOG score,NLR,PLR,and LMR,a nomogram prediction model for the prognosis of advanced non-small cell lung cancer patients treated with PD-1 inhibitor is constructed,which has important clinical application value.
5.Precision diagnosis of hepatocellular carcinoma.
Zhenxiao WANG ; Hanjiao QIN ; Shui LIU ; Jiyao SHENG ; Xuewen ZHANG
Chinese Medical Journal 2023;136(10):1155-1165
Hepatocellular carcinoma (HCC) is the most common type of primary hepatocellular carcinoma (PHC). Early diagnosis of HCC remains the key to improve the prognosis. In recent years, with the promotion of the concept of precision medicine and more in-depth analysis of the biological mechanism underlying HCC, new diagnostic methods, including emerging serum markers, liquid biopsies, molecular diagnosis, and advances in imaging (novel contrast agents and radiomics), have emerged one after another. Herein, we reviewed and analyzed scientific advances in the early diagnosis of HCC and discussed their application and shortcomings. This review aimed to provide a reference for scientific research and clinical practice of HCC.
Humans
;
Carcinoma, Hepatocellular/pathology*
;
Liver Neoplasms/pathology*
;
Prognosis
;
Early Diagnosis
;
Precision Medicine
6.Astragaloside in cancer chemoprevention and therapy.
Yaning WANG ; Zhuo ZHANG ; Zhaohua CHENG ; Wei XIE ; Hanjiao QIN ; Jiyao SHENG
Chinese Medical Journal 2023;136(10):1144-1154
Tumor chemoprevention and treatment are two approaches aimed at improving the survival of patients with cancers. An ideal anti-tumor drug is that which not only kills tumor cells but also alleviates tumor-causing risk factors, such as precancerous lesions, and prevents tumor recurrence. Chinese herbal monomers are considered to be ideal treatment agents due to their multi-target effects. Astragaloside has been shown to possess tumor chemoprevention, direct anti-tumor, and chemotherapeutic drug sensitization effects. In this paper, we review the effects of astragaloside on tumor prevention and treatment and provide directions for further research.
Humans
;
Chemoprevention
;
Antineoplastic Agents
;
Neoplasms/prevention & control*
;
Saponins/pharmacology*
;
Triterpenes/pharmacology*
7.Therapeutic effect of PD-1 monoclonal antibody combined with cisplatin or gemcitabine chemotherapy in a mouse xenograft model with KRAS mutant non-small cell lung cancer A549 cells
LI Xiongbing ; ZHOU Ruifen ; LI Jiali ; WANG Hanjiao ; WANG Chao ; LI Jing ; CAO Zhe ; SHU Chengrong
Chinese Journal of Cancer Biotherapy 2024;31(4):371-376
[摘 要] 目的:探讨程序性死亡受体-1(PD-1)单抗联合顺铂或吉西他滨在KRAS基因突变非小细胞肺癌(NSCLC)A549细胞移植瘤小鼠模型治疗中的作用。方法:构建免疫系统-肿瘤双人源化A549细胞小鼠移植瘤模型,将60只小鼠按随机数字表法分成6组(10只/组),分别为对照组(200 μL/kg PBS)、PD-1单抗组(20 mg/kg PD-1单抗)、顺铂组(3 mg/kg顺铂)、PD-1单抗+顺铂组(20 mg/kg PD-1单抗+3 mg/kg顺铂)、吉西他滨组(30 mg/kg吉西他滨)和PD-1单抗+吉西他滨组(20 mg/kg PD-1单抗+30 mg/kg吉西他滨)。TUNEL和DAPI双染色法检测移植瘤组织中细胞凋亡水平,测量移植瘤体积和质量并计算肿瘤生长抑制率,免疫组化法检测移植瘤微血管密度(MVD)。结果:成功构建免疫系统-肿瘤双人源化NSCLC A549细胞小鼠移植瘤模型,PD-1单抗+顺铂组移植瘤的细胞凋亡率、肿瘤生长抑制率均最高,移植瘤体积、质量和MVD均最小,与其他5组小鼠比较差异均有统计学意义(均P<0.05)。结论:顺铂与PD-1单抗具有协同活性,而吉西他滨拮抗PD-1单抗的治疗作用。提示PD-1单抗联合顺铂对KRAS突变NSCLC A549细胞移植瘤小鼠的疗效更好。